A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating PEGylated Loxenatide Injection PEX168 Combined With Metformin in the Treatment of Type 2 Diabetes Mellitus
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 02 Feb 2017
At a glance
- Drugs PEG loxenatide (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Jiangsu Hansoh Pharmaceutical
- 07 Jun 2017 Biomarkers information updated
- 21 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.
- 21 Jan 2017 Status changed from recruiting to active, no longer recruiting.